Unlocking the Mysteries of ADPKD: XORTX Therapeutics’ Research Discovers Surprising Link Between Uric Acid and Disease Progression

Published | Modified April 22, 2024
CSIMarket Newsroom | CSIMarket.com

XORTX Therapeutics Inc. Announces Significant Research Findings in ADPKD

Calgary, Alberta, April 22, 2024 - XORTX Therapeutics Inc. (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANUA WKN: A3UNZ), a leading late-stage clinical pharmaceutical company specializing in the development of innovative therapies for progressive kidney disease, is thrilled to announce the acceptance of their research paper

Source for this article: Based on Xortx Therapeutics Inc ’s official statement

For details on how CSIMarket validates financial and corporate news, please review our Editorial Standards & Fact-Checking Policy .

Comments

Comments are available to active subscribers. Subscribe or Log in.

Get the full CSIMarket dataset: Subscribe API License